O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-6.13%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.66B
AUM Growth
-$817M
(-15%)
Cap. Flow
-$166M
Cap. Flow
% of AUM
-3.56%
Top 10 Holdings %
Top 10 Hldgs %
33.28%
Holding
137
New
14
Increased
16
Reduced
26
Closed
12
Top Buys
| 1 |
Merck
MRK
|
$109M |
| 2 |
Apollomics
APLM
|
$64.9M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$58.2M |
| 4 |
AbbVie
ABBV
|
$49.2M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$45.5M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$95.2M |
| 2 |
UnitedHealth
UNH
|
$87.7M |
| 3 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
$87.7M |
| 4 |
Edwards Lifesciences
EW
|
$48.6M |
| 5 |
Baxter International
BAX
|
$42.8M |
Sector Composition
| 1 | Healthcare | 97.78% |
| 2 | Industrials | 1.11% |
| 3 | Consumer Staples | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Amicus Therapeutics
FOLD
$2.42B
| – | – |
-1,856,400
| Closed | -$23.3M |
|
127
GH Research
GHRS
$870M
| – | – |
-736,315
| Closed | -$8.74M |
|
128
Mersana Therapeutics
MRSN
$34.8M
| – | – |
-288,597
| Closed | -$23.7M |
|
129
Nektar Therapeutics
NKTR
$543M
| – | – |
0
| – | – |
|
130
TG Therapeutics
TGTX
$5.03B
| – | – |
0
| – | – |
|
|
TSVT
131
DELISTED
2seventy bio
TSVT
| – | – |
-2,391,628
| Closed | -$24.2M |
|
132
Travere Therapeutics
TVTX
$1.75B
| – | – |
-2,118,100
| Closed | -$32.5M |
|
133
Zimmer Biomet
ZBH
$20.8B
| – | – |
-245,000
| Closed | -$35.7M |
|
|
RVNC
134
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-100,000
| Closed | -$2.53M |
|
|
DBTX
135
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| – | – |
-4,945,192
| Closed | -$19M |
|